Reviews safety of maribavir in adults with kidney failure and CMV infection after transplant
Reviews medical records on maribavir safety in adults with kidney failure and CMV infection.
Plain-language title generated from the registry record
Registry title: A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Key facts
- Where
- Barakaldo, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, and Seville, SpainSee the 8 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe kidney disease or kidney failure who had a transplant and then got a CMV infection that did not respond to treatment. They must have started maribavir in routine care. Only existing medical records are reviewed.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Kidney failure (ESRD, eGFR below 15 mL/min/1.73m^2, including people on peritoneal dialysis or hemodialysis) or severe chronic kidney disease (eGFR 15 to below 30 mL/min/1.73m^2), diagnosed before the index date. CMV infection that did not respond to treatment (refractory) after transplant.
- Earlier treatment
- Must have had a solid organ transplant or a stem cell transplant before the index date. Must have started maribavir in routine practice and received at least 1 dose.
- Biomarker or test result
- eGFR below 15 mL/min/1.73m^2 for kidney failure, or 15 to below 30 mL/min/1.73m^2 for severe chronic kidney disease.
Main reasons for not taking part
- The record lists no exclusion criteria
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario CrucesBarakaldo, SpainNot yet recruiting
- Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
- Hospital Universitario Vall d'Hebron - PPDSBarcelona, SpainTaking people
- C.H. Regional Reina Sofia - PPDSCórdoba, SpainNot yet recruiting
- Hospital Universitario de BellvitgeL'Hospitalet de Llobregat, SpainNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainNot yet recruiting
- Hospital Regional Universitario de Malaga - Hospital GeneralMálaga, SpainTaking people
- Hospital Universitario Virgen del Rocio - PPDSSeville, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Takeda
- Trial code
- NCT06243731
- Record updated
- 16 December 2025
- Original description
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis).Read full original descriptionShow less
Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis).
In this study, already existing data will be collected from the participant's medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants.
Inclusion: Adults more than and equal to (≥) 18 years of age at index date; Diagnosis of comorbid ESRD or comorbid severe CKD prior to the index date; If ESRD (including participants on peritoneal dialysis or hemodialysis): participant diagnosed with ESRD confirmed by an estimated glomerular filtration rate (eGFR) less than (<) 15 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2); If severe CKD: participant diagnosed with severe CKD confirmed by an eGFR of 15 to <30 mL/min/1.73m\^2 at index; Participant has undergone solid organ transplant (SOT) or hematopoietic stem cell transplantation (HSCT) before index date; Participant was diagnosed with refractory (with or without resistance) CMV during the latest post-transplant period; Participant initiated treatment with maribavir in routine practice within the eligibility period and received at least 1 dose of maribavir; Informed consent provided (where required by local regulations) before data collection commences.
Exclusion: There are no exclusion criteria for this study.